The contractor shall coordinate, maintain and manage nichd participating sites for impaact 2050 / create - phase IV study of the pharmacokinetics of long-acting injectable cabotegravir and rilpivirine…
Active Awarded Last action
- Contract number
- 75N94026F00001
- Awardee
-
Westat, Inc. UEI NVUWAFWQ57S5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,502,640
Award facts
- Contract value 100% obligated
- $2,502,640.00 Current and potential, with all options
- Completion date 2% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Bethesda, MD 20814, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Child Health and Human Development issued a delivery order to Westat, Inc. on September 28, 2026, for coordination, maintenance, and management of NICHD participating sites under the IMPAACT 2050 / CREATE Phase IV study of pharmacokinetics of long-acting injectable cabotegravir and rilpivirine in pregnant and postpartum women with HIV. The order has a ceiling value of $2,502,640 and runs through September 27, 2031, under a cost-plus-fixed-fee pricing structure.
Place of performance is Bethesda, Maryland. The study requires Westat to coordinate and manage research sites participating in the pharmacokinetic evaluation across the performance period. No set-aside was applied to this delivery order.
Description
The contractor shall coordinate, maintain and manage nichd participating sites for impaact 2050 / create - phase IV study of the pharmacokinetics of long-acting injectable cabotegravir and rilpivirine in pregnant and postpartum women with HIV in the
Quick answers
Who was awarded contract 75N94026F00001?
75N94026F00001 was awarded to Westat, Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on September 28, 2026.
How much is contract 75N94026F00001 worth?
The government has obligated $2,502,640 on 75N94026F00001.
Is contract 75N94026F00001 an order under another contract?
Yes. 75N94026F00001 is a delivery order under 75N94023D00001, an indefinite delivery contract.
Was contract 75N94026F00001 competed?
The extent of competition for 75N94026F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award